In a sign that value-based care is here to stay, some practices that did not participate in the Oncology Care Model (OCM) have applied for the Enhancing Oncology Model (EOM).
Fred Divers, MD, chief medical officer, American Oncology Network and medical oncologist, Genesis Cancer and Blood Institute of Arkansas, and moderator Stuart Staggs, MSIE, senior director, strategic programs, The US Oncology Network, said the initial concern about EOM was whether practices would participate, but some have applied to find out more about the model. Stephen Schleicher, MD, MBA, chief medical officer, Tennessee Oncology, said within his network, OneOncology, all 15 practices have applied, even those that did not participate in OCM.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Patient Navigation in Oncology at Heart of Priority Health White House Visit
April 24th 2024On March 27, Priority Health's president and CEO, Praveen Thadani participated in a discussion on how to expand and optimize patient navigation services in oncology care, as part of the Cancer Moonshot initiative.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More